Emil D. Kakkis - 29 Dec 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
29 Dec 2023
Net transactions value
-$1,436,100
Form type
4
Filing time
02 Jan 2024, 16:07:46 UTC
Previous filing
23 Oct 2023
Next filing
08 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Sale $1,436,100 -30,000 -5% $47.87 569,770 29 Dec 2023 Direct F1, F2, F3, F4
holding RARE Common Stock 2,263,985 29 Dec 2023 By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.54 to $48.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Includes 27 shares acquired under the Company's Amended and Restated 2014 Employee Stock Purchase Plan on October 31, 2023.
F4 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.